N-(3-fluoro-4-(methylsulfonamido)benzyl)-3-(4-(trifluoromethyl)phenyl)propanamide | 910534-74-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-fluoro-4-(methylsulfonamido)benzyl)-3-(4-(trifluoromethyl)phenyl)propanamide
• 英文别名: 3-[4-(trifluoromethyl)phenyl]-N-[3-fluoro-4-(methanesulfonylamino)benzyl]propionamide；N-[[3-fluoro-4-(methanesulfonamido)phenyl]methyl]-3-[4-(trifluoromethyl)phenyl]propanamide
• CAS: 910534-74-6
• 化学式: C₁₈H₁₈F₄N₂O₃S
• 分子量: 418.412
• InChiKey: MVSVLUUXMNYKGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-(4-三氟甲基苯基)丙酸 、 3-fluoro-4-(methylsulfonylamino)benzylamine hydrochloride 在 N-甲基吗啉 、 三乙胺 、 4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 以75%的产率得到N-(3-fluoro-4-(methylsulfonamido)benzyl)-3-(4-(trifluoromethyl)phenyl)propanamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists

  摘要：

  We have developed a new class of diarylalkyl amides as novel TRPV1 antagonists. They exhibited potent Ca-45(2+) uptake inhibitions in rat DRG neuron. In particular, the amide 59 was identified as a potent antagonist with IC50 of 57 nM. The synthesis and structure-activity relationship of the diarylalkyl amides are also described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.04.010

文献信息

• WO2006/98554
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSES, ISOMERE DE CEUX-CI OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI EN TANT QU'ANTAGONISTES DU RECEPTEUR VANILLOIDE ; ET COMPOSITION PHARMACEUTIQUE CONTENANT CEUX-CI
  申请人：AMOREPACIFIC CORP

  公开号：WO2006098554A1

  公开（公告）日：2006-09-21

  [EN] This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disease, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, Crohn's disease, a respiratory disease, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.
  [FR] La présent invention concerne de nouveaux composés, un isomère de ceux-ci ou des sels pharmaceutiquement acceptables en tant qu'antagonistes du récepteur vanilloïde (récepteur vanilloïde 1; VR1; TRPV1); ainsi qu'une composition pharmaceutique contenant ceux-ci. Cette invention décrit une composition pharmaceutique destinée à la prévention ou au traitement de maladies telles que la douleur, la migraine, l'arthralgie, la névralgie, les neuropathies, les lésions nerveuses, les maladies cutanées, l'hypersensibilité vésicale, le syndrome du côlon irritable, la défécation impérieuse, la maladie de Crohn, les maladies respiratoires, l'irritation de la membrane cutanée oculaire ou muqueuse, l'ulcère gastrique/duodénal, les maladies inflammatoires ainsi que les maladies auriculaires et cardiaques.
• Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists
  作者：Fu-Nan Li、Nam-Jung Kim、Seung-Mann Paek、Do-Yeon Kwon、Kyung Hoon Min、Yeon-Su Jeong、Sun-Young Kim、Young-Ho Park、Hee-Doo Kim、Hyeung-Geun Park、Young-Ger Suh

  DOI：10.1016/j.bmc.2009.04.010

  日期：2009.5

  We have developed a new class of diarylalkyl amides as novel TRPV1 antagonists. They exhibited potent Ca-45(2+) uptake inhibitions in rat DRG neuron. In particular, the amide 59 was identified as a potent antagonist with IC50 of 57 nM. The synthesis and structure-activity relationship of the diarylalkyl amides are also described. (C) 2009 Elsevier Ltd. All rights reserved.